论文部分内容阅读
目的:探讨沙美特罗替卡松联合噻托溴铵治疗慢性阻塞性肺疾病(COPD)的临床疗效。方法:选取96例COPD患者分为两组:对照组和观察组,两组均给予常规治疗,对照组加用噻托溴铵治疗,观察组加用沙美特罗替卡松联合噻托溴铵治疗,对比两组疗效。结果:治疗后,与治疗前相比,两组患者FEV_1、FEV_1/FVC、FEV_1/预计值、PaO_2均升高,PaCO_2、MMRC评分降低,且以上指标观察组改善程度均优于对照组。两组比较,差异均有统计学意义(P<0.05)。结论:沙美特罗替卡松联合噻托溴铵是临床治疗慢性阻塞性肺疾病的理想方案。
Objective: To investigate the clinical efficacy of salmeterol and titalopyribin combined with tiotropium in the treatment of chronic obstructive pulmonary disease (COPD). Methods: Ninety-six patients with COPD were divided into two groups: the control group and the observation group. Both groups were given routine treatment and the control group was treated with tiotropium. The observation group was treated with salmeterol and titalopyribin Treatment, the two groups were compared. Results: After treatment, FEV_1, FEV_1 / FVC, FEV_1 / predictive value, PaO_2, PaCO_2 and MMRC scores decreased in both groups compared with that before treatment, and the improvements of the above indexes in the observation group were better than those in the control group. The differences between the two groups were statistically significant (P <0.05). Conclusion: Salmeterol ticlazide combined with tiotropium is an ideal clinical treatment of chronic obstructive pulmonary disease.